Related Experiment Videos
Topical misoprostol therapy for plasma cell vulvitis: a case series
Jennifer Gunter1, Loren Golitz
1The University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA. jennifer.gunter@uchsc.edu
Journal of Lower Genital Tract Disease
|July 27, 2005
Summary
Topical misoprostol offers a novel treatment for plasma cell vulvitis, a rare vulvar condition. This case series reports successful resolution of pain and lesions in three patients refractory to other therapies.
Area of Science:
- Dermatology
- Gynecology
Background:
- Plasma cell vulvitis is a rare, benign, and often painful vulvar condition.
- It is characterized by chronic inflammation and lesions, frequently resistant to standard treatments.
Observation:
- This study presents a case series of three women diagnosed with plasma cell vulvitis.
- These patients had not responded to conventional therapies for their vulvar pain and lesions.
Findings:
- Topical misoprostol, compounded in white petrolatum, was administered to three patients.
- All patients experienced complete resolution of vulvar pain and lesions within six weeks.
- A 0.01% concentration was well-tolerated, while a 0.02% concentration caused local side effects.
Implications:
- Topical misoprostol represents a promising new therapeutic option for plasma cell vulvitis.
- The immunosuppressive properties of misoprostol are suggested as the mechanism for its efficacy.
- Further research is warranted to confirm these findings and optimize treatment protocols.